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Lassa fever, a viral hemorrhagic disease, is 
a growing threat to public health in West 
Africa and beyond. While Ebola virus dis-
ease (EVD) recently captured the attention 
of the global community, Lassa fever argu-
ably represents an even more concerning 
cause of viral hemorrhagic fever (VHF). 
Unlike EVD, which causes sporadic out-
breaks, Lassa virus (LASV) is endemic in 
West Africa and is responsible for an esti-
mated 300 000 infections and >5000 deaths 
annually—figures that are likely underes-
timates, given the challenge of collecting 
epidemiologic data due to civil conflict 
and limited clinical research infrastructure 
in endemic countries [1–3]. As a result, 
in a given 3 year period, Lassa fever kills 
more people than all the known outbreaks 
of EVD combined. Moreover, the World 
Health Organization (WHO) reports an 
upward trend in the incidence of Lassa 
fever this past year, perhaps as a conse-
quence of climate change, with an increase 
in severity and case fatality rate [4]. Many 
of these deaths could be prevented with 
better diagnostics, supportive clinical care, 
and therapeutics [4, 5]. Furthermore, with 
>32 reported cases of Lassa fever imported
into nonendemic countries—one-third
of which were fatal—the significance of
enhanced detection and management of
this virus extends beyond West Africa
[6–10]. For these reasons, in 2016, the 
WHO released a research and develop-
ment blueprint call to action that iden-
tified LASV as a “top priority emerging 
pathogen” likely to cause a severe out-
break in the near future and consequently 
urgently needing to be studied [11].
Despite being a major cause of infec-
tion in West Africa, Lassa fever remains 
underdiagnosed and understudied. It has 
been almost 50 years since LASV was 
first identified during a 1969 outbreak in 
Nigeria, but the mechanisms underlying 
its pathogenesis and the role that host and 
viral factors play remain unclear. With the 
notable exception of tenacious efforts by 
research groups at Kenema Government 
Hospital in Sierra Leone a Irrua Specialist 
Teaching Hospital in Nigeria, Lassa fever 
clinical research has been largely petrified. 
Limited studies from the 1980s suggest 
that uncontrolled viremia is highly pre-
dictive of disease severity [12]. Patients 
presenting with systemic viral loads <103 
median 50% tissue culture infective dose 
(TCID50)/mL were 3.7 times more likely 
to survive than those admitted with 
higher levels [13]. Additionally, survival 
has also been linked to the induction of 
a LASV-specific cell-mediated immune 
response, rather than a humoral immune 
response, as the appearance of antibodies 
does not seem to impact viremia and neu-
tralizing antibodies do not appear until 
months to years after the acute infection 
[13]. Beyond this, there is limited under-
standing of human immune responses to 
LASV infection, as civil conflict in Sierra 
Leone and Liberia and the subsequent 
decimation of the healthcare infrastruc-
ture in the region have effectively halted 
Lassa fever research and, importantly, 
impeded the care of infected patients.
The report by McElroy and colleagues 
in this issue of The Journal of Infectious 
Diseases provides an alternative strategy 
to advance the science of Lassa fever and 
the care of infected patients. Capitalizing 
on the opportunity presented when a 
healthcare worker with acute Lassa fever 
was repatriated from West Africa to 
Emory University Hospital in Atlanta, 
McElroy and colleagues, in a collabora-
tion with the Centers for Disease Control 
and Prevention, conducted an in-depth 
investigation to characterize the kinetics, 
magnitude, and quality of the innate and 
cellular immune response during primary 
LASV infection, while also providing 
advanced clinical care. Although they 
detail the immune response of a single 
patient, the comprehensive nature of their 
analysis offers a rare insight into the inter-
action of a high-consequence pathogen 
with a human host and an opportunity to 
identify critical aspects that require fur-
ther investigation. After a tragically pro-
longed pause in Lassa fever research, the 
work reported by these investigators is an 
important step in moving the science of 
this neglected virus into the 21st century.
The detailed analysis of the kinetics of 
the immune response revealed a correla-
tion between multiple components of 
the immune response and viral clearance 
including interferon alpha (IFN-α) expres-
sion, the appearance of LASV-specific 
immunoglobulin M (IgM), and increas-
ing activated CD8+ T cells. The IFN-α 
findings support prior work in nonhu-
man primate models of Lassa fever link-
ing IFN-α levels with survival as well as 
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in vitro experiments of LASV-infected 
macrophages in which decreased viral 
replication in the presence of IFN-α and 
the persistence of LASV replication in 
IFNR–/– mice [14, 15]. Although IgM lev-
els correlated with viral clearance, the late 
appearance of neutralizing antibodies and 
a high neutralizing antibody requirement 
for protection in passive transfer experi-
ments suggest that the IgM is unlikely to 
be protective. However, the authors offer 
alternative roles for the humoral response, 
including antibody-dependent comple-
ment fixation, which could be further eval-
uated in models of Lassa fever. Perhaps of 
most interest is that CD8+ T cells demon-
strated biphasic activation: The first cor-
related with viral clearance, but the second 
occurring peak coincided with markers of 
proliferation and the expression of per-
forin and granzyme B and corresponded 
to the onset of diffuse lymphadenitis and 
epididymitis more than a month after 
symptom onset, in the absence of detect-
able viremia. Sustained activated CD8+ T 
cells during convalescence strongly sug-
gests the persistence of LASV or viral anti-
gen, further supported by the detection of 
LASV in the patient’s semen beyond clear-
ance of viremia. Collectively, this detailed 
immunologic study of a single patient 
highlights not only the potential role of 
IFN-α in viral clearance and the longitudi-
nal immunophenotyping of CD8+ T cells 
during Lassa fever, but also identifies a 
finding of profound public health signifi-
cance that requires further investigation—
the seminal persistence of LASV.
Although LASV is found in virtually 
every body fluid and compartment during 
acute infection, little is known about the 
viral kinetics of LASV in body fluids other 
than blood. This case report provides fur-
ther evidence that, despite the clearance of 
virus from the blood, some survivors con-
tinue to shed virus or viral RNA in immu-
nologically protected compartments, 
including the urogenital system. Semen 
was positive by quantitative reverse-tran-
scription polymerase chain reaction on 
days 15, 20 and 48, with evidence of virus 
isolation on day 20 [14]. In the absence 
of a systematic survey or a validated test 
for urogenital fluids, it is not known for 
how long male survivors shed LASV in 
semen, or whether the virus can be found 
in female genital fluids. The implications 
of viral persistence in such immune sanc-
tuaries are now just being recognized 
as a potential source of new outbreaks 
through sexual transmission for a num-
ber of other emerging infectious viruses, 
including Ebola and Zika viruses [15–17]. 
Therefore, although this case report tells 
the story of one man, the identification of 
viral persistence in semen draws critical 
attention to the need to follow survivors 
longitudinally after clearance of viremia 
and to apply validated assays to the study 
of LASV in body fluids other than blood.
Lassa fever is among the most import-
ant, but underrecognized, VHF public 
health threats. The recent EVD outbreak 
that quickly devastated parts of West 
Africa and triggered a public health cri-
sis infected >28 000 individuals and killed 
>11 000. Because of the endemic nature of 
LASV, Lassa fever causes even more suf-
fering, albeit at a slower and steadier pace. 
Fortunately, the repatriated healthcare
worker described in this report survived.
But many of those in the Lassa fever–
endemic region who become infected
do not survive, and there has been little
reason for hope. The work presented here
provides a blueprint for further research
on the immune response and viral per-
sistence during acute and convalescent
Lassa fever and we hope that this work can 
be translated into improved clinical care.
In the wake of the most recent EVD 
outbreak, infrastructure for EVD sur-
veillance, case management, and clini-
cal research has been developed in West 
Africa, but still no such capability exists 
for Lassa fever, despite the predictable 
ongoing toll of this contagious disease. 
Vast sums were invested into the building 
of this infrastructure to respond to and 
research EVD in West Africa, and these 
resources should serve a dual purpose 
by allowing the growing clinical research 
community in the region to conduct more 
in-depth and collaboratory studies of this 
persistent threat. Laboratories stood up 
to provide Ebola virus diagnostics, and 
these could be turned toward developing 
validated and accessible assays for LASV 
detection. Infection control procedures 
implemented during the EVD outbreak 
could become routine in medical facili-
ties where Lassa fever is endemic, so that 
healthcare workers can be protected. The 
processes that allowed for epidemiological 
data collection of EVD cases can also be 
applied to providing reasonable estimates 
of the toll and location of Lassa fever that 
can direct public health resources. Thirty 
years ago, an outbreak of horrific violence 
halted Lassa fever research. The recent 
outbreak of Ebola can and should resur-
rect this effort so that the people of West 
Africa, who suffer so greatly, can be free of 
its constant and deadly presence.
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